Label-free characterization of challenging transmembrane proteins using Alto™ digital SPR

Play Video


Transmembrane proteins (TPs) serve as crucial conduits between the internal and external environments of cells, regulating ion and molecule passage and orchestrating cellular responses to external cues. They play pivotal roles in cellular signaling, cell-cell interactions, and various physiological processes, making them promising targets for novel therapeutics, including cell and gene therapies. Leveraging the unique properties of TPs, researchers can design targeted therapeutic strategies with improved efficacy, specificity, and safety profiles.

However, isolating biologically relevant forms of TPs, particularly multi-pass TPs, presents formidable challenges due to their intricate structures and limited expression levels. Addressing this demand, ACROBiosystems has pioneered cutting-edge technology platforms tailored to the complexities of multi-pass TPs. This innovation has yielded a comprehensive suite of full-length, stabilized multi-pass TPs, including key therapeutic targets such as CD20, Claudin18.2, CD133, and others. Engineered to maintain native folding and high activity, these proteins serve as invaluable tools for advancing drug development and uncovering novel mechanisms of action.
In collaboration with Nicoya, a cutting-edge technology company dedicated to supporting drug development through advanced analytical solutions, Nicoya’s Alto™ digital surface plasmon resonance (SPR) system was utilized to characterize the binding kinetics of several transmembrane proteins in detergent, nanodisc, and virus-like particle (VLP) formats. This webinar will showcase how the Alto digital SPR system provides high-quality data on challenging membrane protein candidates while significantly reducing sample consumption and time to results. Through this collaboration, researchers and pharmaceutical developers gain access to advanced technologies that enable the production, stabilization and precise characterization of challenging transmembrane protein interactions, accelerating the development of novel therapeutics and unlocking new frontiers in therapeutic targeting.


Headshot of Michael Piazza
Dr. Michael Piazza
Director of Applications Development
Dr. Anil Kumar
Head of CMC in Europe


Resources referenced in the webinar have been linked below.

As the world’s only surface plasmon resonance (SPR) system powered by digital microfluidics, Alto™ revolutionizes real-time interaction analysis by eliminating the need to compromise on quality and time. Go from sample to answer within hours while streamlining even the toughest of biologics applications with Alto’s intuitive and automated ecosystem. Designed to take the complexity out of SPR, Alto™ will empower your team with the data they need to take their discoveries to the next level.

Read it here.

Alto’s comprehensive software, the Nicosystem, provides a one-stop centralized hub for acquisition and analysis of real-time binding data, all while offering an intuitive user interface, one-click analysis feature, and the flexibility of accessing your experiments from anywhere.

Learn more here.

Many human diseases are known to be associated with transmembrane proteins (TPs), making them ideal candidates for drug development. Multi-pass transmembrane proteins are not stable outside of the cell membrane environment, and are therefore difficult to purify and to express in large quantities. This has resulted in the under-characterization of a critical group of biomolecules. One strategy for overcoming these challenges is to use vectors that closely mimic cell membranes, such as nanodiscs. In this application note, Alto Digital SPR was used to characterize binding kinetics of Claudin-18.2 in nanodiscs from ACROBiosystems, demonstrating its ability to provide high-quality data while significantly reducing precious sample consumption and time to results.

Read it here.

Other webinars you might like

Questions or comments about the webinar?
Speak with an application scientist today!